» Articles » PMID: 21070867

PPARβ/δ Activation Blocks Lipid-induced Inflammatory Pathways in Mouse Heart and Human Cardiac Cells

Overview
Specialties Biochemistry
Biophysics
Date 2010 Nov 13
PMID 21070867
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Owing to its high fat content, the classical Western diet has a range of adverse effects on the heart, including enhanced inflammation, hypertrophy, and contractile dysfunction. Proinflammatory factors secreted by cardiac cells, which are under the transcriptional control of nuclear factor-κB (NF-κB), may contribute to heart failure and dilated cardiomyopathy. The underlying mechanisms are complex, since they are linked to systemic metabolic abnormalities and changes in cardiomyocyte phenotype. Peroxisome proliferator-activated receptors (PPARs) are transcription factors that regulate metabolism and are capable of limiting myocardial inflammation and hypertrophy via inhibition of NF-κB. Since PPARβ/δ is the most prevalent PPAR isoform in the heart, we analyzed the effects of the PPARβ/δ agonist GW501516 on inflammatory parameters. A high-fat diet induced the expression of tumor necrosis factor-α, monocyte chemoattractant protein-1, and interleukin-6, and enhanced the activity of NF-κB in the heart of mice. GW501516 abrogated this enhanced proinflammatory profile. Similar results were obtained when human cardiac AC16 cells exposed to palmitate were coincubated with GW501516. PPARβ/δ activation by GW501516 enhanced the physical interaction between PPARβ/δ and p65, which suggests that this mechanism may also interfere NF-κB transactivation capacity in the heart. GW501516-induced PPARβ/δ activation can attenuate the inflammatory response induced in human cardiac AC16 cells exposed to the saturated fatty acid palmitate and in mice fed a high-fat diet. This is relevant, especially taking into account that PPARβ/δ has been postulated as a potential target in the treatment of obesity and the insulin resistance state.

Citing Articles

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hayes C, Gallucci G, Boyer J, Assis D, Ghonem N Hepatol Commun. 2024; 9(1).

PMID: 39699308 PMC: 11661771. DOI: 10.1097/HC9.0000000000000612.


Metabolic flux in macrophages in obesity and type-2 diabetes.

Wong A, Sun Q, Latif I, Karwi Q J Pharm Pharm Sci. 2024; 27:13210.

PMID: 38988822 PMC: 11233469. DOI: 10.3389/jpps.2024.13210.


Genistein and sex hormone treatment alleviated hepatic fat accumulation and inflammation in orchidectomized rats with nonalcoholic steatohepatitis.

Okrit F, Chayanupatkul M, Wanpiyarat N, Siriviriyakul P, Werawatganon D Heliyon. 2024; 10(4):e26055.

PMID: 38380011 PMC: 10877361. DOI: 10.1016/j.heliyon.2024.e26055.


Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas.

Souza-Tavares H, Miranda C, Vasques-Monteiro I, Sandoval C, Santana-Oliveira D, Silva-Veiga F World J Gastroenterol. 2023; 29(26):4136-4155.

PMID: 37475842 PMC: 10354577. DOI: 10.3748/wjg.v29.i26.4136.


Small molecule-mediated rapid maturation of human induced pluripotent stem cell-derived cardiomyocytes.

Chirico N, Kessler E, Maas R, Fang J, Qin J, Dokter I Stem Cell Res Ther. 2022; 13(1):531.

PMID: 36575473 PMC: 9795728. DOI: 10.1186/s13287-022-03209-z.